Recent advances in antibody engineering have provided a number of functionally optimized anti-EpCAM antibodies.38 Anti-EpCAM antibody conjugated with alpha-amanitin has the potential to be a highly effective therapeutic agent for pancreatic carcinoma and various EpCAM-expressing malignancies.39 Since 1970s, the method of MD simulation has gained popularity in biochemistry and biophysics.40 The aim of this study was to offer a reasonable pattern of anti-EpCAM IT model to design the novel generation of recombinant IT. The gene discussed is EPCAM; the disease is exocrine pancreatic carcinoma.